Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has received aggregate gross proceeds of approximately CAD$590,000 through the exercise of previously issued common share purchase warrants and the closing of a corporate loan.
The Company reports that holders of previously issued warrants exercised an aggregate of 4,103,023 warrants for total gross proceeds of approximately $340,000 (the "Warrant Exercises"). Of this amount, the Company's Chief Executive Officer exercised 1,303,023 warrants for gross proceeds to the Company of approximately $130,000.
In addition, the Company has entered into an arm's length loan agreement pursuant to which the amount will be CAD$250,000 in principal funding (the "Loan Financing"). The loan bears interest at a rate of 12% per annum, payable monthly and has a term of twelve (12) months, and includes an option to renew upon mutual agreement of the parties. The loan is subject to customary terms and conditions.
The Company intends to use the net proceeds from the Warrant Exercises and Loan Financing to advance its previously announced binding letter of intent dated December 22, 2025 to acquire 100% of the capital of Holy Crap Foods Inc. from Happy Belly Food Group (CSE: HBFG) (the "Proposed Acquisition"), as well as advancing its intended Food Studies and for general working capital purposes, as further described in the Company's news releases dated December 22, 2025 and December 17, 2025. Completion of the Proposed Acquisition remains subject to customary conditions, including but not limited to the completion of satisfactory due diligence, the negotiation and entry into a definitive agreement, and applicable regulatory approvals, including the approval of the CSE.
Restart Life Sciences extends its appreciation to shareholders for their continued support as the Company advances its mission and executes on its strategic growth initiatives.
About Restart Life Sciences Corp.
Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.
Forward-Looking Statements
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements relating to the repayment of the loan under the Loan Financing, the use of proceeds from the Warrant Exercises and Loan Financing, and completion of the Proposed Acquisition, including the receipt of CSE approval.
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the inherent risks and uncertainties relating to the Loan Financing, the Company receiving CSE approval of the Proposed Acquisition, the Company's financial condition, market volatility; the state of the financial markets for the Company's securities; the ability for the Company to make its loan repayments on time; and general business, economic, competitive, political and social uncertainties;. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, the continued availability of capital and financing, receipt of CSE approval of the Proposed Acquisition, the parties' entry into the definitive agreement and satisfaction of all conditions precedent; and the current and future social, economic and political conditions.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those expressed or implied in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. Readers are encouraged to read the Company's continuous disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
On behalf of the Board of Directors
Steve Loutskou
Chief Executive Officer, Restart Life Sciences Corp.
Tel: +1 (778) 819-0244
Email: hello@restartlife.co
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278802
The Company reports that holders of previously issued warrants exercised an aggregate of 4,103,023 warrants for total gross proceeds of approximately $340,000 (the "Warrant Exercises"). Of this amount, the Company's Chief Executive Officer exercised 1,303,023 warrants for gross proceeds to the Company of approximately $130,000.
In addition, the Company has entered into an arm's length loan agreement pursuant to which the amount will be CAD$250,000 in principal funding (the "Loan Financing"). The loan bears interest at a rate of 12% per annum, payable monthly and has a term of twelve (12) months, and includes an option to renew upon mutual agreement of the parties. The loan is subject to customary terms and conditions.
The Company intends to use the net proceeds from the Warrant Exercises and Loan Financing to advance its previously announced binding letter of intent dated December 22, 2025 to acquire 100% of the capital of Holy Crap Foods Inc. from Happy Belly Food Group (CSE: HBFG) (the "Proposed Acquisition"), as well as advancing its intended Food Studies and for general working capital purposes, as further described in the Company's news releases dated December 22, 2025 and December 17, 2025. Completion of the Proposed Acquisition remains subject to customary conditions, including but not limited to the completion of satisfactory due diligence, the negotiation and entry into a definitive agreement, and applicable regulatory approvals, including the approval of the CSE.
Restart Life Sciences extends its appreciation to shareholders for their continued support as the Company advances its mission and executes on its strategic growth initiatives.
About Restart Life Sciences Corp.
Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.
Forward-Looking Statements
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements relating to the repayment of the loan under the Loan Financing, the use of proceeds from the Warrant Exercises and Loan Financing, and completion of the Proposed Acquisition, including the receipt of CSE approval.
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the inherent risks and uncertainties relating to the Loan Financing, the Company receiving CSE approval of the Proposed Acquisition, the Company's financial condition, market volatility; the state of the financial markets for the Company's securities; the ability for the Company to make its loan repayments on time; and general business, economic, competitive, political and social uncertainties;. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, the continued availability of capital and financing, receipt of CSE approval of the Proposed Acquisition, the parties' entry into the definitive agreement and satisfaction of all conditions precedent; and the current and future social, economic and political conditions.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those expressed or implied in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. Readers are encouraged to read the Company's continuous disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
On behalf of the Board of Directors
Steve Loutskou
Chief Executive Officer, Restart Life Sciences Corp.
Tel: +1 (778) 819-0244
Email: hello@restartlife.co
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278802